Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01643941 · ClinicalTrials.gov registry record · Phase 1
Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 284
- Enrollment target
NCT01643941 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 284 participants.
The verdict
NCT01643941, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 284 participants
- Enrollment target
Study Summary
This is a Phase 1 and Phase 2 study of a single vaccination with one of three dose levels of a 4-antigen investigational vaccine against Staphylococcus aureus (SA4Ag) and a single dose level of a 3-antigen Staphylococcus aureus vaccine (SA3Ag). The main goal of the study is to determine how safe and well tolerated the vaccine is as well as to describe the immune response elicited by the vaccine in healthy adults aged 65 to \<86 years. In addition, the study aims to assess the effect of the Staphylococcus aureus vaccine on the presence of the Staphylococcus aureus within the nose, throat and perineal skin of healthy adults aged 65 to \<86 years.
Interventions
- PROCEDURE Blood draw
- BIOLOGICAL SA4Ag vaccine low dose
- PROCEDURE Colonization swab sample
- BIOLOGICAL SA4Ag vaccine mid dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01643941
The ClinicalTrials.gov registry entry for NCT01643941 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Blood draw is the first listed.
NCT01643941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01643941 about?
NCT01643941 is a clinical study titled "Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years". This is a Phase 1 and Phase 2 study of a single vaccination with one of three dose levels of a 4-antigen investigational vaccine against Staphylococcus aureus (SA4Ag) and a single dose level of a 3-antigen Staphylococcus aureus vaccine (SA3Ag). The main goal of the study is to determine how safe and...
What is the current status of trial NCT01643941?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 284 participants. The study started on 2012-08. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01643941?
The interventions under investigation include: Blood draw (PROCEDURE), SA4Ag vaccine low dose (BIOLOGICAL), Colonization swab sample (PROCEDURE), SA4Ag vaccine mid dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT01643941?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.